Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Cerilliant
Daiichi Sankyo
US Department of Justice
Fuji
Federal Trade Commission
Dow
Baxter
Argus Health
McKesson

Generated: August 16, 2017

DrugPatentWatch Database Preview

Tesaro Inc Company Profile

« Back to Dashboard

What is the competitive landscape for TESARO INC, and when can generic versions of TESARO INC drugs launch?

TESARO INC has two approved drugs.

There are ten US patents protecting TESARO INC drugs.

There are one hundred and eighty-eight patent family members on TESARO INC drugs in forty-four countries.

Summary for Applicant: Tesaro Inc

Patents:10
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tesaro Inc
ZEJULA
niraparib tosylate
CAPSULE;ORAL208447-001Mar 27, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tesaro Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,902,366NK.sub.1 antagonists► Subscribe
9,345,692Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-s- piro[4.5]decan-2-one and treatment methods using the same► Subscribe
8,273,895NK.sub.1 antagonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tesaro Inc Drugs

Country Document Number Estimated Expiration
China101578279► Subscribe
Japan6041919► Subscribe
Japan5823476► Subscribe
Germany602008005711► Subscribe
Cyprus1111584► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
Merck
Federal Trade Commission
Fuji
UBS
Novartis
US Department of Justice
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot